Drug interactions in oncology: how common are they?

Drug interactions in oncology: how common are they?

Author Riechelmann, Rachel P. Autor UNIFESP Google Scholar
Del Giglio, A. Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
ABC Sch Med
Abstract Methods: We searched PubMed for eligible articles and on-line databases for abstracts of major oncology meetings.Results: Eight studies reported on the frequency of DDIs: six evaluated the frequency of potential DDIs, while two studies reported on real DDIs, i.e. interactions that had clinical consequences. Studies of potential DDIs found that approximately one-third of patients are exposed to dangerous drug doublets, with the most common ones involving warfarin and anticonvulsants. One study of real DDIs found that 2% of hospitalized cancer patients had a DDI as the cause of admission.Conclusions: Drug interactions comprise an important issue in oncology, with approximately one-third of ambulatory cancer patients being at risk of DDIs. Data are limited on the clinical consequences of drug interactions among cancer patients.
Keywords adverse effects
drug interactions
drug therapy
Language English
Date 2009-12-01
Published in Annals of Oncology. Oxford: Oxford Univ Press, v. 20, n. 12, p. 1907-1912, 2009.
ISSN 0923-7534 (Sherpa/Romeo, impact factor)
Publisher Oxford Univ Press
Extent 1907-1912
Origin http://dx.doi.org/10.1093/annonc/mdp369
Access rights Open access Open Access
Type Review
Web of Science ID WOS:000272179000002
URI http://repositorio.unifesp.br/handle/11600/31959

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account